International cohort studies suggest that adding azithromycin to hydroxychloroquine (HCQ) treatment may increase heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length of ECG. Severe adverse events associated with HCQ-azithromycin were compared to HCQ-amoxicillin in rheumatoid arthritis patients aged 18+ and followed up over 30 days. A total of 323,122 and 351,956 users of HCQ-azithromycin and HCQ-amoxicillin were included. When azithromycin was added to HCQ, an increased risk of 30-day cardiovascular mortality (HR2.19), chest pain/angina (HR 1.15), and heart failure (HR 1.22) were observed. HCQ is a drug for malarial and for systemic lupus erythematosus. It recently received Emergency Use Authorization by the FDA for use to treat COVID-19 patients. Source: https://www.medrxiv.org/
Early-life sugar restriction during pregnancy and infancy was associated with a 34% lower risk of…
Higher levels of physical activity were associated with lower risks of all-cause dementia, Alzheimer’s disease,…
In US adults aged ≥65 years, overweight and class I–II obesity were associated with lower…
In community-dwelling older adults without prior cardiovascular disease (CVD), new or persistent heart stress (HS)—defined…
In the German multicenter study of 5,521 patients with colorectal cancer (CRC), the apparent survival…
In adults aged 75 years or older without a history of atherosclerotic cardiovascular disease (ASCVD)…
This website uses cookies.